The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion regarding Amylyx Pharmaceuticals Inc's AMLX conditional marketing authorization of AMX0035 (Albrioza) for amyotrophic lateral sclerosis (ALS).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,